Literature DB >> 10883420

The absolute bioavailability of oral melatonin.

R L DeMuro1, A N Nafziger, D E Blask, A M Menhinick, J S Bertino.   

Abstract

The absolute bioavailability of oral melatonin tablets was studied in 12 normal healthy volunteers. Subjects were administered, in a randomized crossover fashion, melatonin 2 mg intravenously and 2 and 4 mg orally. Blood was sampled over approximately eight (estimated) half-lives. Both the 2 and the 4 mg oral dosages showed an absolute bioavailability of approximately 15%. No difference in serum half-life was seen in any of the study phases. Oral melatonin tablets in dosages of 2 and 4 mg show poor absolute bioavailability, either due to poor oral absorption, large first-pass metabolism, or a combination of both. Further studies examining larger doses, in an attempt to saturate first-pass metabolism if it occurs, may be warranted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883420     DOI: 10.1177/00912700022009422

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  49 in total

1.  Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behaviour management strategies: a randomised controlled crossover trial.

Authors:  Barry Wright; David Sims; Siobhan Smart; Ahmed Alwazeer; Ben Alderson-Day; Victoria Allgar; Clare Whitton; Heather Tomlinson; Sophie Bennett; Jenni Jardine; Nicola McCaffrey; Charlotte Leyland; Christine Jakeman; Jeremy Miles
Journal:  J Autism Dev Disord       Date:  2011-02

2.  A three pulse phase response curve to three milligrams of melatonin in humans.

Authors:  Helen J Burgess; Victoria L Revell; Charmane I Eastman
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

Review 3.  Clinical pharmacokinetics of melatonin: a systematic review.

Authors:  Nathja Groth Harpsøe; Lars Peter Holst Andersen; Ismail Gögenur; Jacob Rosenberg
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

4.  Poor Quality Control of Over-the-Counter Melatonin: What They Say Is Often Not What You Get.

Authors:  Madeleine M Grigg-Damberger; Dessislava Ianakieva
Journal:  J Clin Sleep Med       Date:  2017-02-15       Impact factor: 4.062

5.  Melatonin in children with autism spectrum disorders: endogenous and pharmacokinetic profiles in relation to sleep.

Authors:  Suzanne E Goldman; Karen W Adkins; M Wade Calcutt; Melissa D Carter; Robert L Goodpaster; Lily Wang; Yaping Shi; Helen J Burgess; David L Hachey; Beth A Malow
Journal:  J Autism Dev Disord       Date:  2014-10

6.  Melatonin pharmacokinetics following two different oral surge-sustained release doses in older adults.

Authors:  Nalaka S Gooneratne; Alena Y Z Edwards; Chen Zhou; Norma Cuellar; Michael A Grandner; Jeffrey S Barrett
Journal:  J Pineal Res       Date:  2012-02-21       Impact factor: 13.007

Review 7.  Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal.

Authors:  David E Blask; Robert T Dauchy; Leonard A Sauer
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

8.  Electrochemical detection of exogenously administered melatonin in the brain.

Authors:  Elisa Castagnola; Kevin Woeppel; Asiyeh Golabchi; Moriah McGuier; Neharika Chodapaneedi; Julian Metro; I Mitch Taylor; X Tracy Cui
Journal:  Analyst       Date:  2020-02-19       Impact factor: 4.616

Review 9.  Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress.

Authors:  Edzard Schwedhelm; Renke Maas; Raphael Troost; Rainer H Böger
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 10.  Physiological and metabolic functions of melatonin.

Authors:  J Barrenetxe; P Delagrange; J A Martínez
Journal:  J Physiol Biochem       Date:  2004-03       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.